🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase Registry Leukemia Journal share.google/xjKvfUiq02R08y…

Excited to share our latest study published in Leukemia (Leukemia Journal): Characterization of E1 enzyme dependencies in mutant-UBA1 human cells reveals UBA6 as a novel therapeutic target in VEXAS syndrome nature.com/articles/s4137…

Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL) | Leukemia nature.com/articles/s4137…

Time for a paradigm shift in immunotherapy-based BCMA/CD3 bispecific drug development in multiple myeloma | Leukemia ⁦Vincent Rajkumar⁩ nature.com/articles/s4137…

Just published: on behalf of the European LeukemiaNet, the international expert panel led by Prof Jane Apperley presented the 2025 management recommendations of chronic myeloid leukemia (CML) in LEUKEMIA Leukemia Journal open access. nature.com/articles/s4137…

Just published: On behalf of the European LeukemiaNet, an international expert panel led presented the 2025 update of the management recommendations of chronic myeloid leukemia #CML in the journal LEUKEMIA Leukemia Journal open access. nature.com/articles/s4137…

2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia Leukemia Journal share.google/alq3q3MPhoJhLR…

Solitary but not Simple Risk stratification and individualized treatment in solitary plasmacytoma. ⁦Leukemia Journal⁩ nature.com/articles/s4137…

Read the latest on solitary plasmacytoma Leukemia Journal Saurabh Zanwar Mayo Myeloma nature.com/articles/s4137…

Patterns of relapse in patients with multiple myeloma receiving chimeric antigen receptor T cell therapy: a multi-center analysis Leukemia Journal share.google/l29tQjauJ6WOV2…

Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes | Leukemia nature.com/articles/s4137…

Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL) | Leukemia nature.com/articles/s4137…

Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera | Leukemia nature.com/articles/s4137…

Senescence profiling of monoclonal gammopathies reveals paracrine senescence as a crucial defense against disease progression | Leukemia nature.com/articles/s4137…

Time for a paradigm shift in immunotherapy-based BCMA/CD3 bispecific drug development in multiple myeloma | Leukemia nature.com/articles/s4137…

Measurable Residual Disease in Haematological and Solid Cancers nature.com/collections/fh…

Just out! Current Risk stratification of all Plasma Cell Disorders. MGUS, SMM, Myeloma, Amyloidosis. We paid Open Access fees so you can download and read freely! Lots of Tables. Bookmark. Saurabh Zanwar Shaji Kumar Leukemia Journal Link: nature.com/articles/s4137…

There are many risk stratification models available for MGUS, and SMM, and Myeloma etc. We highlight the ones we use and recommend for practice. Mayo Myeloma Mayo Clinic Comprehensive Cancer Center 1/ Myeloma Our risk stratification uses and builds on the IMS IMWG High risk definition.

Mayo Myeloma Mayo Clinic Comprehensive Cancer Center 2/ Smoldering Myeloma We recommend the Mayo 2018 20-2-20 criteria which have been validated by the IMWG and are currently referred to as the IMWG2020 criteria.

A one stop shop for the current risk stratification schema in plasma cell disorders! As always, thank you for being so generous with your time Vincent Rajkumar! Absolutely wonderful experience learning the art of scientific communication from the very best! #mmsm #bookmark